This week, we have a conversation with Vidmantas Šakalys, CEO of bioprinting company Vital3D Technologies, and a chat with Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx, another of the companies that attended the American Association for Cancer Research (AACR) annual meeting in Chicago recently.Interview times:01:47 Vital3D Technologies20:46 AOA DxVital3D TechnologiesLithuanian company <a target="_blank" href="https://vital3d.eu/">Vital3D Technologies</a> is developing 3D bioprinting technology aimed at bridging the organ supply-demand gap by specializing in the 3D printing of human organs.As the company progresses on its journey towards printing organs like the kidneys, via printing human skin, Vital3D Technologies has made practical, ready-to-use applications along the way - one of them being organoid application for drug testing.Bioprinting shows particular promise in cancer treatment by producing tumour models from patient-derived cells. With instances of cancer on the rise globally and the mean cost of cancer drug development estimated at $4.4bn per drug, bioprinting has the potential to alleviate some of the many stressors currently affecting the healthcare system.We have a conversation with the company’s CEO, Vidmantas Šakalys.AOA Dx<a target="_blank" href="https://aoadx.com/">AOA Dx</a>, an early-stage biotech company developing the first test to diagnose ovarian cancer in symptomatic women, and Sonrai Analytics recently announced a strategic partnership to accelerate the development of AOA’s multi-omic liquid biopsy test.The partnership aims to advance the development of the diagnostic test through a multi-omic biomarker validation strategy.AOA Dx is transforming cancer detection with its proprietary GlycoLocate platform, a first-of-its-kind, multi-omics liquid biopsy that integrates gangliosides, lipids, proteins, and clinical data using advanced machine learning.The company’s lead test, AKRIVIS GD, is designed to diagnose ovarian cancer in symptomatic women, where no other diagnostic currently exists.Our conversation is with Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx.To get in touch with guest suggestions, please email <a target="_blank" href="mailto:jim@deeptechdigest.com">jim@deeptechdigest.com</a>

Base to Base biotech podcast 10: 3D printing human organs and early detection of ovarian cancer